Pioneering biopharma company Neurocentrx have developed an abuse-deterrent, oral-ketamine therapy for Treatment-Resistant Depression(TRD), which has the potential to provide a convenient, cost-effective means to reduce the high medical morbidity, socio-economic burden, and individual patient suffering associated with TRD